Foggia

• Efficacy and safety of adjunctive IgM-enriched immunoglobulin therapy with a personalized dose based on serum IgM-titers vs. standard dose i … Recruiting
  2024-518096-57-00 5 2024-11-11 Septic shock
• A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-fibrosis) Recruiting
  2023-509912-27-00 5 2024-11-07 Metabolic Dysfunction-Associated Steatotic Liver Disease(MASH) / Nonal
• Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH (ENLIGHTEN-Cirrhosis) Recruiting
  2023-510395-31-00 5 2024-10-30 Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Compensat
• A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Recruiting
  2023-509706-30-00 5 2024-10-18 Heart failure (HF)
• A follow-up study to test long-term treatment with BI 1015550 in people with pulmonary fibrosis who took part in a previous study with BI 10 … Recruiting
  2023-507353-15-00 5 2024-09-10 idiopathic pulmonary fibrosis (IPF)
• Randomized phase 3 study of intermittent or continuous Panitumumab plus FOLFIRI for first-line treatment of patients with unresectable left … Recruiting
  2023-509551-14-00 5 2024-06-12 Unresectable left sided RAS/B-RAF wild-type metastatic colorectal canc
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non-Cirrho … Recruiting
  2023-505141-48-00 5 2024-03-07 Fibrosis
• A Phase 3, prospective, randomized, double-blind, placebo-controlled, parallel group, international, multi-center study of rotigotine in com … Recruiting
  2023-504602-11-00 5 2023-10-25 Mild to moderate Alzheimer's disease
• Randomized phase 2 study of Valproic acid combinEd with Simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic P … Recruiting
  2024-518710-11-00 4 2023-06-12 Metastatic pancreatic ductal adenocarcinoma (mPDAC)
• "APalutamide and stEReotactic body radiation therapy for low burden metastatic hormone senSItive prostate cancer, a rANdomized trial -PERSIA … Recruiting
  2022-501894-37-00 4 2023-03-02 prostate cancer
• A study of tucatinib with trastuzumab and mFOLFOX6 versus standard of care treatment in first-line HER2+ metastatic colorectal cancer Recruiting
  2024-514180-25-00 5 2022-11-21 unresectable or metastatic HER2+ colorectal cancer
• Randomised phase III trial of ADT +/- darolutamide in frail men with castration-naïve de novo metastatic prostate cancer Recruiting
  2022-502425-18-00 5 2022-04-19 Adenocarcinoma of the prostate
• Low INR to Minimize bleeding with mechanical valves Trial (LIMIT) Recruiting
  2023-508532-56-00 5 2021-10-19 Treatment with a Vitamin K Antagonist due to having a mechanical bilea
• The study is aimed at evaluating the feasibility of a hypomethylating treatment combined with hematopoietic stem cell transplantation in com … Recruiting
  2023-510515-19-00 5 2020-11-27 Higher-risk-myelodysplastic syndromes
• Study to determine the efficacy of Gemtuzumab Ozogamicin, together with standard chemotherapy, on minimal residual disease levels, in adult … Recruiting
  2023-510433-29-00 5 2020-09-24 Favorable-intermediate-risk Acute Myeloid Leukemia
• Metformin versus Tolvaptan in adults with Autosomal Dominant Polycystic Kidney Disease (ADPKD): a phase 3a, independent, multi-centre, 2 par … Recruiting
  2024-517864-49-01 5 2020-09-08 Autosomal Dominant Polycystic Kidney Disease
• Trial aimed at examinate the functionality and effectiveness of the drug "IO" in adult patients with a rare form of cancer that affect the c … Recruiting
  2023-510516-39-00 4 2019-10-30 Acute B-cell Lymphoblastic Leukemia with minimal residual positive dis
• Bacille Calmette-Guérin (BCG) vaccine in Radiologically Isolated Syndrome (RIS) Recruiting
  2024-518901-16-00 4 2019-07-29 RIS (Radiologically Isolated Syndrome)
• Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Progressive Metastatic Castration- … Ended recruitment
  2024-513968-25-00 5 2025-04-28 Metastatic castration-resistant prostate cancer (mCRPC)
• Efficacy and safety study of frexalimab (SAR441344) in adults with nonrelapsing secondary progressive multiple sclerosis Ended recruitment
  2023-504359-29-01 5 2024-12-11 Multiple sclerosis
• A 26-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Axatilimab … Ended recruitment
  2022-502954-15-00 4 2024-06-21 Idiopathic pulmonary fibrosis
• A study to investigate long-term safety and tolerability of itepekimab in participants with COPD Ended recruitment
  2023-508085-15-00 5 2024-05-15 Chronic Obstructive Pulmonary Disease
• A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination with Chemotherapy for the First Line Treatment for Pati … Ended recruitment
  2022-502043-35-01 5 2024-04-24 Advanced Biliary Tract Cancers
• A Phase III Study to assess efficacy, safety, and tolerability of Zibotentan combined with Dapagliflozin, compared to Dapagliflozin, in pati … Ended recruitment
  2023-504124-26-00 5 2024-04-04 Chronic Kidney Disease and High Proteinuria

Showing 49–72 of 102 trials